HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.8%

Neg 0% Neu 87.8% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.